A psychosocial model of a medical problem: Maternal phenylketonuria
S Shiloh1, S E Waisbren, H L Levy
1Institute for Child Development, Sheba Medical Center, Tel-Hashomer, Israel.
Insights
Maternal phenylketonuria (PKU) management requires strict dietary adherence for offspring health. A new psychosocial model outlines four reproductive stages to improve patient coping and treatment success for women with PKU.
Area of Science:
- Reproductive health
- Metabolic disorders
- Psychosocial adjustment
Background:
- Maternal phenylketonuria (PKU) treatment involves a low phenylalanine diet to prevent adverse offspring outcomes.
- Poor patient adherence to medical recommendations is a significant challenge in managing maternal PKU.
- Understanding psychosocial factors is crucial for improving treatment adherence.
Purpose of the Study:
- To present a psychosocial model for adjustment and coping in maternal PKU.
- To define behavioral goals across four key reproductive stages for women with PKU.
- To identify psychosocial factors influencing adherence to dietary management.
Main Methods:
- Literature review on behaviors and psychosocial factors related to maternal PKU management.
- Development of a four-stage psychosocial model for the reproductive years of women with PKU.
- Analysis of factors contributing to success or failure in achieving behavioral goals at each stage.
Main Results:
- The model identifies four distinct stages: pregnancy prevention, reproductive decision-making, diet initiation, and diet continuation.
- Psychosocial factors influencing adherence were identified for each stage.
- The framework provides insights into challenges and potential interventions for maternal PKU management.
Conclusions:
- A structured psychosocial model can enhance understanding of maternal PKU management.
- Targeted interventions addressing psychosocial factors at each reproductive stage may improve patient adherence.
- This model offers a theoretical basis for practical clinical strategies in maternal PKU care.
Abstract:
Treatment of maternal phenylketonuria (PKU) consists of a low phenylalanine diet, begun before conception, which is believed to prevent mental retardation, microcephaly, and congenital heart disease in offspring of women with PKU. Experiences in treating these women indicate that their cooperation with medical recommendations is generally poor. We present a psychosocial model on adjustment and coping in maternal PKU. The proposed model defines four stages in the reproductive years of women with PKU, each of which has specific behavioral goals. The four stages are: (1) prevention of unplanned pregnancies; (2) reproductive decision-making; (3) diet initiation; and (4) diet continuation through pregnancy. Review of the literature on the different behaviors expected at the different stages enabled indentification of psychosocial factors that may explain success or failure in achieving the goals at each stage. Based on this theoretical framework, practical implications for treating women with PKU have been suggested.
More Related Videos
05:04A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect
Published on: September 22, 2023
05:44Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Related Concept Videos
Inborn Errors of Metabolism
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Models of Health Promotion and Illness Prevention I
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
Teratogenicity
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
